Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others.
Last trade$30.51
Day change-$0.04 (-0.13%)
Day range$29.48 – $31.00
Volume301,831
Market cap$2.12B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$2.12B
Price / earnings
—
Price / book
6.99×
Price / sales
19.49×
EV / sales
18.37×
EV / EBITDA
-45.04×
Profitability
Earnings per share
-$0.80
Return on assets
-14.78%
Return on equity
-18.4%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
9.49×
Quick ratio
7.87×
Cash ratio
3.63×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.47M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for ALMR, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Revenue
$33.55M
$29.43M
Cost of revenue
$12.9M
$11.71M
Gross profit
$20.64M
$17.72M
Selling, general and administrative
$19.62M
$17.43M
Research and development
$16.17M
$13.82M
Total operating expenses
$35.78M
$31.25M
Operating income
-$15.14M
-$13.53M
Interest expense
-$153K
-$224K
Income before taxes
-$13.25M
-$13.29M
Income taxes
$94K
-$93K
Net income
-$13.34M
-$13.2M
Net income attributable to common shareholders
-$13.34M
-$13.2M
EBITDA
-$13.72M
-$12.4M
Basic earnings per share
-$0.19
-$0.22
Diluted earnings per share
-$0.19
-$0.22
Recent news
Company coverage with links to the original publishers.
Alamar Biosciences reported Q3 2026 revenue of $33.55 million, flat year-over-year, beating the consensus estimate of $30.13 million by 11.35%. EPS came in at -$0.19, outperforming the estimated -$0.22 by 13.64%. The company showed strength in service revenue and consumables, though the stock has declined 24.1% over the past month. Alamar holds a Zacks Rank #2 (Buy) rating.
Alamar Biosciences and Nightingale Health announced a major collaboration to conduct the UKB-PRISM study, measuring blood-based protein biomarkers in 80,000 UK Biobank samples to identify early molecular indicators of neurodegenerative diseases including Parkinson's and Alzheimer's. The study, funded by The Michael J. Fox Foundation, Alzheimer's Research UK, and LifeArc, will be completed by end of 2027 and create an open-access resource for researchers worldwide.
A longitudinal study published in The Lancet Neurology using Alamar Biosciences' NULISAseq CNS 120 panel found that patients receiving lecanemab for early symptomatic Alzheimer's disease show markedly different biological responses. The research revealed that biomarkers associated with amyloid clearance differ from those associated with cognitive decline, explaining why clearing amyloid doesn't produce uniform clinical benefits across patients. The study measured 130 plasma proteins across 2,385 samples from 1,967 participants.
Alamar Biosciences announced a national research initiative in collaboration with top universities to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq™ Neuro 220 detection kit. The resulting dataset will be made publicly available through the National Alzheimer's Coordinating Center to support AI-driven research and accelerate biomarker discovery for neurodegenerative diseases.
Alamar Biosciences announced a national-scale proteomics initiative in collaboration with Washington University, University of Wisconsin, and Indiana University to analyze approximately 21,000 plasma samples from 10,000 Alzheimer's Disease and Related Dementias (ADRD) participants using its NULISAseq Neuro 220 multiplex panel. The resulting open-access dataset will be linked to the National Alzheimer's Coordinating Center and will support AI-driven biomarker discovery and validation for neurodegenerative diseases.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.